Who are Peg-P-IFN-alpha-2b (AOP2014)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PegIFN alfa-2a, Pegylated-Proline-interferon alpha-2b.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peg-p-ifn-alpha-2b-aop2014.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Peg-P-IFN-alpha-2b (AOP2014) — Competitive Intelligence Brief

Peg-P-IFN-alpha-2b (AOP2014) (Peg-P-IFN-alpha-2b (AOP2014)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pegylated interferon alpha. Area: Virology / Immunology.

phase 3 Pegylated interferon alpha Interferon alpha receptor (IFNAR) Virology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Peg-P-IFN-alpha-2b (AOP2014) (Peg-P-IFN-alpha-2b (AOP2014)) — AOP Orphan Pharmaceuticals AG. Peg-P-IFN-alpha-2b is a pegylated interferon alpha-2b that activates innate immune responses to suppress viral replication and enhance antiviral immunity.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Peg-P-IFN-alpha-2b (AOP2014) TARGET	Peg-P-IFN-alpha-2b (AOP2014)	AOP Orphan Pharmaceuticals AG	phase 3	Pegylated interferon alpha	Interferon alpha receptor (IFNAR)
PegIFN alfa-2a	PegIFN alfa-2a	The Second Affiliated Hospital of Chongqing Medical University	marketed	Pegylated interferon alpha	Interferon-alpha receptor (IFNAR)
Pegylated-Proline-interferon alpha-2b	Pegylated-Proline-interferon alpha-2b	AOP Orphan Pharmaceuticals AG	phase 3	Pegylated interferon alpha	Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pegylated interferon alpha class)

AOP Orphan Pharmaceuticals AG · 2 drugs in this class
The Second Affiliated Hospital of Chongqing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Peg-P-IFN-alpha-2b (AOP2014) — Competitive Intelligence Brief. https://druglandscape.com/ci/peg-p-ifn-alpha-2b-aop2014. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab